CoffeeNCT07051291
Acute Effects of Instant Coffee in Capsule vs Beverage Form on Plasma Metabolites
A study testing Instant Coffee Capsule and Instant Coffee Beverage in people with Coffee, run by National University of Singapore at 1 site in Singapore.
Trial summary
This study is designed to evaluate the acute effect of consuming a cup of instant coffee on circulating metabolites and to evaluate whether ingestion of instant coffee in the form of a capsule has a similar effect on circulating metabolites as compared to the conventionally prepared beverage. Read more about this study
- Who is it for?
- Ages 21 to 64 yearsHealthy volunteers can take part
- Conditions the study is for
- Coffee
- What is being tested?
- Instant Coffee Capsule and Instant Coffee Beverage
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 1 siteSingapore
- Study dates
- 22 Sep 2020to 10 Oct 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 64 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
None listed.
Who cannot join
- Pregnant or breastfeeding
- Certain medications including Zanaflex, Sirasalud, Ketanest S, Spravato and Ephedrine Sulfate
- Any pre-existing medical conditions, depression, anxiety, caffeine/lactose intolerant, fear of needles and/or blood disorders, allergy to coffee or bovine capsules
- Existing dietary restrictions which makes them unable to consume non-halal certified bovine gelatin (the capsule encasing the coffee powder)
- Recent history of major surgical operations in the past year
- Past or current user of oral/systemic hormone treatment or therapies
Show all 10Show fewer
- Taken antibiotics in the last 3 months
- Taking nutritional supplements (that contains coffee/tea-related compounds naturally found in other plants)
- Not willing to travel to the University for the study
- Unable to commit to completing both study visits
Trial locations and contacts
1 site in 1 country.
Singapore1 site
Saw Swee Hock School of Public Health, National University of Singapore
Singapore, 117549
About this study
Official title: The Acute Effect of Instant Coffee in Different Forms on Plasma Metabolites
This study is designed to evaluate the acute effect of consuming a cup of instant coffee on circulating metabolites and to evaluate whether ingestion of instant coffee in the form of a capsule has a similar effect on circulating metabolites as compared to the conventionally prepared beverage.
- Conditions
- Coffee
- Being tested
- Instant Coffee Capsule, Instant Coffee Beverage
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Instant Coffee CapsuleDietary supplement
Participants received 1.7 grams of instant coffee in the form of three capsules. 200 mL of plain water was provided to participants to swallow the three capsules.
Instant Coffee BeverageDietary supplement
Dissolved 1.7 grams of instant coffee in 200 mL of hot water to make a coffee beverage.
| Study group | Role | What they receive |
|---|---|---|
| Instant coffee capsule/ coffee beverage | Experimental | Not described Receives: Dietary Supplement: Instant Coffee Capsule; Dietary Supplement: Instant Coffee Beverage |
| Instant coffee beverage/ coffee capsule | Experimental | Not described Receives: Dietary Supplement: Instant Coffee Capsule; Dietary Supplement: Instant Coffee Beverage |
What is being measured
The primary outcome is the main question the study is designed to answer.
Caffeine and polyphenol metabolites
Each participant underwent two interventions, and blood was collected pre- and post- each intervention. Blood was allowed to clot at room temperature. After 30-40 min, serum was separated from entire blood by centrifugation (3000g, 15 min, 4°C) and aliquoted into tubes. All samples were processed on the same day of collection. A total of 7 biomarker compounds (trigonelline, paraxanthine, theophylline, theobromine, caffeine, cyclo(Leu-Pro), and cyclo(Pro-Val)) were quantified using a targeted method developed in-house. The quantification method was optimized by LC retention elution, parent-daughter quantifier mass transitions, and varying MS cone and collision energies (in V) to obtain clear peak separation and height. Multiple Reaction Monitoring (MRM) in positive electrospray ionization mode was performed on a Waters Xevo TQ-S Triple Quadrupole Mass Spectrometer system.
Measured: The period between the two study visits ranged between 7 to 28 days.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jul 2025
- Study start22 Sep 2020
- Primary completion10 Oct 2020
- Study completion10 Oct 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CoffeeStudies of the same condition, open and under way.
- More trials run by National University of SingaporeThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Participants will receive both interventions (instant coffee capsule and instant coffee beverage) in a randomized order across two visits.
- Masking
- None (open label)
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- National University of Singapore
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Seow Wei Jie, National University of Singapore
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07051291
- Sponsor's protocol ID
- NUS-IRB-2021-464
- Status last verified
- Jun 2025
- First submitted
- 1 Jun 2025
- Last updated
- 4 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Acute Effect of Instant Coffee in Different Forms on Plasma Metabolites
- ClinicalTrials.gov ID
- NCT07051291
- Acronym / sponsor ID
- NUS-IRB-2021-464
- Conditions
- Coffee
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 15 participants (actual)
- Lead sponsor
- National University of SingaporeUniversity, hospital or other
- Study start
- 22 Sep 2020 (actual)
- Primary completion
- 10 Oct 2020 (actual)
- Study completion
- 10 Oct 2022 (actual)
- First posted
- 4 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is designed to evaluate the acute effect of consuming a cup of instant coffee on circulating metabolites and to evaluate whether ingestion of instant coffee in the form of a capsule has a similar effect on circulating metabolites as compared to the conventionally prepared beverage.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Participants will receive both interventions (instant coffee capsule and instant coffee beverage) in a randomized order across two visits.
| Arm | Type | Receives |
|---|---|---|
| Instant coffee capsule/ coffee beverage | Experimental | Dietary Supplement: Instant Coffee Capsule, Dietary Supplement: Instant Coffee Beverage |
| Instant coffee beverage/ coffee capsule | Experimental | Dietary Supplement: Instant Coffee Capsule, Dietary Supplement: Instant Coffee Beverage |
Who may qualify
- Ages
- 21 to 64 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (0 listed)
Key exclusion criteria (10 listed)
- Pregnant or breastfeeding
- Certain medications including Zanaflex, Sirasalud, Ketanest S, Spravato and Ephedrine Sulfate
- Any pre-existing medical conditions, depression, anxiety, caffeine/lactose intolerant, fear of needles and/or blood disorders, allergy to coffee or bovine capsules
- Existing dietary restrictions which makes them unable to consume non-halal certified bovine gelatin (the capsule encasing the coffee powder)
- Recent history of major surgical operations in the past year
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Instant Coffee CapsuleParticipants received 1.7 grams of instant coffee in the form of three capsules. 200 mL of plain water was provided to participants to swallow the three capsules. | Dietary supplement | Instant coffee beverage/ coffee capsule, Instant coffee capsule/ coffee beverage |
| Instant Coffee BeverageDissolved 1.7 grams of instant coffee in 200 mL of hot water to make a coffee beverage. | Dietary supplement | Instant coffee beverage/ coffee capsule, Instant coffee capsule/ coffee beverage |
Primary outcome
Caffeine and polyphenol metabolites
Time frame: The period between the two study visits ranged between 7 to 28 days.
Each participant underwent two interventions, and blood was collected pre- and post- each intervention. Blood was allowed to clot at room temperature. After 30-40 min, serum was separated from entire blood by centrifugation (3000g, 15 min, 4°C) and aliquoted into tubes. All samples were processed on the same day of collection. A total of 7 biomarker compounds (trigonelline, paraxanthine, theophylline, theobromine, caffeine, cyclo(Leu-Pro), and cyclo(Pro-Val)) were quantified using a targeted method developed in-house. The quantification method was optimized by LC retention elution, parent-daughter quantifier mass transitions, and varying MS cone and collision energies (in V) to obtain clear peak separation and height. Multiple Reaction Monitoring (MRM) in positive electrospray ionization mode was performed on a Waters Xevo TQ-S Triple Quadrupole Mass Spectrometer system.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Jul 2025.
- Individual participant dataSharing planned: No
Related trials for Coffee
Active, not recruiting
Effect of Coffee Smelling on Pain, Physiological Parameters and Time to Discharge From Post Anesthesia Care Unit in Patients Undergoing Laparoscopic Cholecystectomy
Cholecystectomy, Laparoscopic
Recruiting
Effects of Caffeine on Chess Performance and Cognitive Function in Professional Chess Players
Cognitive Performance, Attention
Not yet recruitingObservational study
Coffee Use, Physical Activity and Symptomatic Ventricular Arrhythmias in Patients With Left Ventricular Dysfunction and an ICD
HFrEF - Heart Failure With Reduced Ejection Fraction, HFmrEF
RecruitingPhase 2/3
Caffeine Consumption and Rate Control in Permanent Atrial FIBrillation: The CAFIB Trial
Atrial Fibrillation (AF), Permanent Atrial Fibrillation
Not yet recruiting
The Impact of Coffee Consumption Immediately Before a Nap on Post-Nap Grumpiness
Irritability
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Instant Coffee Capsule and Instant Coffee Beverage in people with Coffee, run by National University of Singapore at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Caffeine and polyphenol metabolites (time frame: The period between the two study visits ranged between 7 to 28 days.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jul 2025.